Hansa Biopharma AB Stock price Nasdaq Stockholm
Equities
SE0002148817
Biotechnology & Medical Research
Sales 2024 * | 265M 24.81M | Sales 2025 * | 402M 37.68M | Capitalization | 1.53B 144M |
---|---|---|---|---|---|
Net income 2024 * | -627M -58.7M | Net income 2025 * | -576M -53.93M | EV / Sales 2024 * | 8.63 x |
Net Debt 2024 * | 753M 70.48M | Net Debt 2025 * | 956M 89.52M | EV / Sales 2025 * | 6.18 x |
P/E ratio 2024 * |
-2.81
x | P/E ratio 2025 * |
-3.43
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anders Pedersen
BRD | Director/Board Member | 73 | 18-05-28 |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
1st Jan change | Capi. | |
---|---|---|
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-5.11% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
-8.77% | 11.06B |